Castleview Partners’s Elanco Animal Health ELAN Stock Holding History

Castleview Partners’s Portfolio ELAN Stock Details ELAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20	Closed	-$244	–	679
2022 Q4	$244	Buy	+20	New	+$249	﹤0.01%	610

Other funds holding ELAN

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Shapiro Capital Management Atlanta, Georgia $1.65B AUM 26.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Castleview Partners's ELAN Position: Q1 2023 in Review

Castleview Partners sold out of Elanco Animal Health (ELAN) in Q1 2023, closing a stake of 20 shares — an estimated $244 sold.

Castleview Partners first reported a position in ELAN in Q4 2022 and held it in 1 quarter. The position peaked at $244 in Q4 2022. 389 funds tracked by Wall St. Rank hold ELAN as of Q1 2023.

Castleview Partners reported no remaining Elanco Animal Health position as of Q1 2023 after selling out during the quarter.
Castleview Partners sold 20 Elanco Animal Health shares in Q1 2023, an estimated $244.
Castleview Partners first reported a position in Elanco Animal Health in Q4 2022 and held it in 1 quarter.
Castleview Partners's Elanco Animal Health position peaked at $244 in Q4 2022.
389 funds tracked by Wall St. Rank held Elanco Animal Health as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.